# A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

> **NCT02135302** · PHASE1 · COMPLETED · sponsor: **Tetraphase Pharmaceuticals, Inc** · enrollment: 24 (actual)

## Conditions studied

- Impaired Hepatic Function

## Interventions

- **DRUG:** eravacycline

## Key facts

- **NCT ID:** NCT02135302
- **Lead sponsor:** Tetraphase Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2014-02
- **Final completion:** 2014-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02135302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02135302, "A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02135302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*